The Biosciences Accelerator at The Hamner Institutes for Health Sciences is a unique resource for start-up companies that provides substantial infrastructure to assist their commercialization efforts. The Biosciences Accelerator provides emerging companies with access to a research facility with state-of-the-art equipment, as well as world-class scientific and business development support through The Hamner's ACE™ incubator services.
ACE™ Services -- short for Accelerating Commercialization and Entrepreneurship -- offers support services to Accelerator businesses and entrepreneurs, including: consulting, marketing, management, administration, and operations. Furthermore, the Biosciences Accelerator fosters opportunities to develop collaborative research and educational programs among The Hamner, academia, industry, and government. Partnerships build shared resources and increase funding opportunities, which add value for each of the participants. This allows The Hamner, in collaboration with its institutional partners, to accelerate the commercialization of new technologies aimed at improving human health.
Current Hamner Biosciences Accelerator Companies
BindusChem, LLC is a chemistry-based contract research service organization with a core business of custom synthesis. The company offers a variety of synthetic chemistry services (from mg to kg quantities) to customers in a cost-effective and timely manner, specializing in small molecules, porphyrins, nucleosides and nucleotides, and heterocycles. BindusChem binds to customer focus, reliability and confidentiality.
Biomedomics, Inc. (www.biomedomics.com/)
BioMedomics is developing advanced highly sensitive and quantitative rapid point-of-care (POC) diagnostic platforms and novel disease specific diagnostic tests for the $16 billion POC diagnostic market. The company’s goal is to make POC testing widely accessible with the same level of sensitivity and quantitation as complex and expensive central lab tests.
Chaperone Therapeutics, Inc. (http://www.chaperonetherapeutics.com/)
Chaperone Therapeutics, Inc. (“Chaperone”) is an early-phase pharmaceutical company that is developing drugs to treat diseases associated with abnormal protein folding and aggregation. Many neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, prion diseases, ALS (Lou Gehrig’s Disease) and Huntington’s disease are characterized by the abnormal aggregation of proteins in individuals with environmental exposure to proteotoxic stress or genetic vulnerability to the disease. Proteins that guide correct protein folding, chaperones, function as the cellular quality control mechanism to correct protein misfolding and to protect neurons from cell death. Chaperone is uniquely poised to develop novel drugs to ameliorate neurodegenerative disease based on the pharmacological enhancement of the body’s natural protein folding machinery.
chemQ bioscience LLC (www.vitroprep.com)
At chemQ bioscience, we use our extensive knowledge of chemistry and chemical compounds and their interaction with living organisms to develop novel clinical liquid-based cytology processing products. Our mission is to develop high quality affordable clinical cytology processing products without utilizing any expensive and complex automation. In fact, our technology requires no automation and our processing procedure is simple that can be adapted in any laboratory and can be practiced by medical lab personnel around the world. We are excited to introduce our first product, VitroPrep™ Cytology Processing Kit that consists of two proprietary solutions: PreservPlus™ and CytoBase™. Our products are ISO 13485 compliant and CE certified. For more information regarding our company and products please visit our website at www.vitroprep.com.
Cloud Pharmaceuticals (www.cloudpharmaceuticals.com)
Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners.
Couragen Biopharmaceutics (email@example.com)
Couragen Biopharmaceutics, LLC is a North Carolina startup biotechnology company whose mission is to develop gene therapy and protein therapy products for pre-clinical and clinical use. Couragen uses a technology platform based on adeno-associate virus (AAV) vectors, a safe and powerful vehicle, to deliver therapeutic genes to a variety of cells, tissues and even the whole body for genetic and chronic diseases treatment. In addition, the company also provides custom-designed AAV vectors, which are in high demand as a tool for laboratory research such as molecular biology, genetics and mechanisms of pathogenesis and even engineering of animal models.
DILIsym Services, Inc. (www.dilisymservices.com)
DILIsym Services, Inc. is a startup company based in Research Triangle Park, NC committed to providing the pharmaceutical industry with the tools, resources and information to efficiently develop safer drug therapies that increase the availability of vital therapeutics for the patients who need them. DILIsym® Services, Inc. is a Delaware “C” corporation. DILIsym® modeling software allows users to carry out in vitro to in vivo extrapolation, translate preclinical results to clinical trial protocol design, and to evaluate the impact of patient variability on predicted hepatotoxicity. Simulations provide a better understanding of how in vitro assay results relate to Drug Induced Liver Injury (“DILI”) responses in animals and people. The DILIsym Services, Inc. expert scientific team engages the client from initial program design through data input and results interpretation.
Genetron Health (www.genetronhealth.com/en/)
Genetron Health is a world-leading patient oriented healthcare company specialized in cancer precision diagnostics. Genetron Health is dedicated to providing the most accurate and timely precision diagnostics to help individuals evaluate cancer risk and to help cancer patients by facilitating the most comprehensive personalized cancer treatment options. The team of international experts and scientists at Genetron Health embraces over 20 years of experience in genetic research and translational medicine. Possessing state-of-the-art proprietary molecular diagnostics and bioinformatics platforms, Genetron Health has produced dozens of top-level research papers as well as numerous international patents. Genetron Health also has long-term cooperation with Duke University and Johns Hopkins University.
MedBlue Incubator (919-226-3082)
MedBlue Incubator, Inc. (MBI) is a for profit C corporation founded by the departments of Surgery, Pathology and Anesthesiology at the Duke University Medical Center. The mission of MBI will be to help identify promising IP in the aforementioned Duke departments and to work seamlessly within those departments and with the Duke Office of Licensing & Ventures to advance the development of the IP to a liquidity event.
Phoundry Pharmaceuticals Inc.
Phoundry Pharma’s passion is to do outstanding science to enable the discovery and development of valuable, highly differentiated peptide therapeutic drugs that will meet the unmet needs of patients. Our core expertise, chemistry, biology, and drug metabolism and pharmacokinetics, provides the means for our stringentselection and validation of peptide targets and the thorough optimization of peptide ligands to clinical candidates. While our discovery and optimization engine is therapeutically agnostic, we have unique and proven expertise in discovering peptide drugs for metabolic diseases. Phoundry Pharma’s capabilities and expertise include; 1) efficient peptide synthesis and development of structure-activity relationships to optimize pharmacokinetics, potency, and drug properties for suitable peptide delivery platforms, 2) a physiological and pharmacological understanding of peptide hormones coupled with an in-depth assessment of in vitro and in vivo potency and selectivity, 3) sophisticated methodologies to assess and optimize peptide hormone analogs’ in vivo half-life, and 4) experience and methodologies to assess and progress singleton or combination peptide therapies.
ProteoVec is a privately held biotechnology company. With headquarters recently relocated to the Hamner Institutes in Research Triangle Park, North Carolina, ProteoVec has developed the LigaTrap technology: a platform for generating highly stable low molecular weight affinity ligands attached to resins or membranes. ProteoVec also offers custom development of completely novel affinity ligands in the same highly robust format for other classes of proteins. In addition, ProteoVec assists companies in search of economical and rapid preclinical protein expression and manufacturing services in state-of-the-art disposable systems.
Triangle Research Labs, LLC (www.triangleresearchlabs.com/)
Triangle Research Labs (TRL) produces high quality hepatocytes for use in pre-clinical ADMETox applications. Their mission is to assist in the discovery and development of meaningful therapeutic agents that benefit the human condition. TRL provides both human and animal, fresh and cryopreserved hepatocytes, and their relevant media. A rapidly growing company, TRL has decades of experience in the hepatic sciences and is a leader in quality and service in the business.
For more information on the Hamner Biosciences Accelerator, please submit the form on the Contact Us page, with “Biosciences Accelerator” selected from the drop-down menu under “Interest.”